Results 281 to 290 of about 63,407 (320)

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath   +2 more
wiley   +1 more source

Macrophage‐targeted cerium‐tannic acid metal‐polyphenol framework nanoenzyme promotes in situ heart valves regeneration through adaptive immunomodulation

open access: yesBMEMat, EarlyView.
A novel nanoenzyme based on cerium ions‐tannic acid metal‐polyphenol framework (FCT) has been developed and loaded onto DHVs for targeting M1 macrophages to reduce their ROS level and reprogram macrophage phenotype, thereby eliminating inflammation, promoting endothelialization and adaptive matrix remodeling of scaffolds, offering a promising strategy ...
Peng Song   +9 more
wiley   +1 more source

Eudragit®‐engineered pH‐responsive probiotic microspheres with enhanced gastrointestinal resistance and prolonged storage stability for inflammatory bowel disease therapy

open access: yesBMEMat, EarlyView.
This study reports the development of AMS@Eud core‐shell microspheres, combining calcium alginate and pH‐responsive Eudragit® L100, which exhibit exceptional gastrointestinal resistance and long‐term storage stability (only 5.28%–9.09% viability loss over 35 days at 4–25°C), and effectively alleviate inflammatory bowel disease via gut microbiota ...
Ming Teng   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy